-
公开(公告)号：US20250059218A1
公开(公告)日：2025-02-20
申请号：US18893468
申请日：2024-09-23
Inventor： Lingyin Li , Mark Smith , Jacqueline Ann Carozza , Volker Boehnert
IPC: C07F9/6512 , A61K31/44 , A61K31/4706 , A61K31/517 , A61K31/675 , A61K31/69 , A61K45/06 , A61P35/00 , C07D215/46 , C07D401/04 , C07F5/02 , C07F9/60 , C07F9/6558
Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell impermeable. ENPP1 inhibitor compounds can act extracellularly to block the degradation of cGAMP. Also provided are pharmaceutical compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of an ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject in conjunction with administering an ENPP1 inhibitor to the subject. The radiation therapy can be administered in the subject methods at a dosage and/or frequency effective to reduce radiation damage to the subject, but still instigate an immune response.
-
公开(公告)号：US12215086B2
公开(公告)日：2025-02-04
申请号：US17582851
申请日：2022-01-24
Applicant: University of Tennessee Research Foundation
Inventor： Ramesh Narayanan , Duane D. Miller , Thamarai Ponnusamy , Dong-Jin Hwang , Yali He
IPC: C07D231/16 , A61K9/00 , A61K31/277 , A61K31/40 , A61K31/415 , A61K31/4164 , A61K31/4192 , A61K31/4196 , A61K31/44 , A61K31/4439 , A61K31/517 , A61K31/5375 , A61K45/06 , C07C255/60 , C07C317/46 , C07D207/06 , C07D207/34 , C07D209/08 , C07D213/84 , C07D233/68 , C07D239/74 , C07D249/04 , C07D249/08 , C07D295/15 , C07D401/12
Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors. R-isomers, and non-hydroxylated and/or non-chiral propenamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic to or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
-
公开(公告)号：US20250034093A1
公开(公告)日：2025-01-30
申请号：US18917759
申请日：2024-10-16
Applicant: Vanderbilt University
Inventor： L. Jackson Roberts, II , Venkataraman Amarnath , David G. Harrison , Annet Kirabo
IPC: C07D213/65 , A61K31/137 , A61K31/44 , C07C215/50 , C07C217/58
Abstract: A method of treating lupus, comprising administering to a patient in need there of an effective gamma-ketoaldehyde scavenging amount of a gamma-ketoaldehyde scavenging compound.
-
公开(公告)号：US12208099B2
公开(公告)日：2025-01-28
申请号：US17275178
申请日：2019-09-09
Applicant: Mirati Therapeutics, Inc.
Inventor： Ruth Wei Aranda , James Gail Christensen , Lars Daniel Engstrom , Jill Hallin , Peter Olson
IPC: A61K31/519 , A61K31/428 , A61K31/4375 , A61K31/44 , A61K31/4985 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K45/06 , A61P35/00
Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
-
公开(公告)号：US20250017856A1
公开(公告)日：2025-01-16
申请号：US18773063
申请日：2024-07-15
IPC: A61K9/127 , A61K9/51 , A61K31/4375 , A61K31/44 , A61K31/565 , A61K31/7088 , A61K45/06
Abstract: A co-formulation comprising: (i) an ionizable colloid forming active substance; (ii) a nucleic acid molecule; and (iii) an amphiphilic molecule. Also, a method of treating a disease or disorder comprising administering the co-formulation to a subject in need, wherein the ionizable colloid-forming active substance and the nucleic acid molecule included in the co-formulation act together in the treatment of the disease or disorder; and a method of manufacturing the co-formulation.
-
公开(公告)号：US20250000870A1
公开(公告)日：2025-01-02
申请号：US18708204
申请日：2022-11-07
Applicant: Cellestia Biotech AG
Inventor： Rajwinder Lehal , Charlotte Urech , Sebastein Lamy
IPC: A61K31/5377 , A61K31/436 , A61K31/4375 , A61K31/44 , A61K31/4745 , A61K31/506 , A61P35/00 , A61P35/02
Abstract: The present invention relates to pharmaceutical combinations comprising a kinase inhibitor and a NOTCH signaling pathway inhibitor and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.
-
公开(公告)号：US12171753B2
公开(公告)日：2024-12-24
申请号：US17837619
申请日：2022-06-10
Applicant: SOPHROSYNE PHARMACEUTICALS LIMITED
Inventor： Lewis Feldberg , Akram Sabouni , Thomas R. Bailey , Vincent Wing-Fai Tai , Tom Leyssens
IPC: A61K31/44 , A61K45/06 , A61P25/32 , C07D211/60
Abstract: Provided herein are novel crystalline forms of a compound that acts as an ALDH2 effector, processes for preparing the crystalline forms of the compound with or without coformer, and uses thereof.
-
公开(公告)号：US20240415787A1
公开(公告)日：2024-12-19
申请号：US18686423
申请日：2022-08-30
Applicant: SHIN POONG PHARMACEUTICAL CO., LTD.
Inventor： Chung JU , Dong Won LEE , Seung Kyu LEE , Sung CHUNG
Abstract: The present invention relates to a pharmaceutical composition or a health functional food for treating or preventing obesity or obesity-related liver disease, containing a verbenone derivative and a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, the verbenone derivative of the present invention is capable of treating and preventing obesity or obesity-related liver disease by inhibiting TGF-β/Smad3 signaling in high-fat diet-induced mice.
-
公开(公告)号：US20240398824A1
公开(公告)日：2024-12-05
申请号：US18741408
申请日：2024-06-12
Applicant: The Johns Hopkins University
Inventor： Seulki Lee , Han Seok Ko , Ted M. Dawson , Martin G. Pomper , Donghoon Kim , Yumin Oh , Seung-Hwan Kwon , Yong Joo Park
IPC: A61K31/5377 , A61K31/44 , A61K31/4439 , A61K31/4709 , A61K31/5025 , A61K31/504 , A61K31/519 , A61K31/529 , A61P25/28
Abstract: Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.
-
公开(公告)号：US12156861B2
公开(公告)日：2024-12-03
申请号：US15734105
申请日：2019-05-31
Inventor： Jie Zhang , Xiaoguang Chen , Wang Huang , Ya Zhang
IPC: A61K31/216 , A61K31/403 , A61K31/44 , A61K31/506 , A61P35/00 , A61K31/192
Abstract: A pharmaceutical composition contains chlorogenic acid and coumaroyl quinic acid. The combined use of chlorogenic acid and coumaroyl quinic acid at a certain ratio can generate a synergistic enhancing effect to effectively inhibit the growth of human kidney cancer cell strain A479, rat kidney cell strain RuCa, and rat transplanted tumor RuCa, providing a novel choice for clinical treatment of kidney cancer and having good market application prospects.
